Clinical Trials Logo

Thoracic Radiotherapy clinical trials

View clinical trials related to Thoracic Radiotherapy.

Filter by:
  • None
  • Page 1

NCT ID: NCT04462276 Active, not recruiting - Clinical trials for Small Cell Lung Cancer Extensive Stage

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease

TREASURE
Start date: July 28, 2020
Phase: Phase 2
Study type: Interventional

This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients. Patients with a response after induction therapy with carboplatin/etoposide and atezolizumab will be included into this study to subsequently receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding radiotherapy and ii.) determine the safety and tolerability of the combination of chemotherapeutic, immunological and radiological treatment in the first-line setting of advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for separate biomarker research project.

NCT ID: NCT03565120 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer

Start date: December 10, 2018
Phase: N/A
Study type: Interventional

This phase II trial studies the safety and efficacy of aggressive thoracic radiotherapy in treating patients with non-small cell lung cancer that has not progressed after the first line systemic therapy. In this trial, patients with stage Ⅳ non small cell lung cancer who did not progress after first line systemic therapy will receive the aggressive thoracic radiotherapy, and the safety and efficacy of aggressive thoracic radiotherapy will be evaluated. The primary end points of the study are overall survival (OS), the secondary end points are local control rate, local progression free survival(LPFS), PFS, and toxicity and quality of life(QOL).